Merck & Co Inc

NYSE:MRK  
79.96
-0.10 (-0.12%)
Products

FDA Grants Accelerated Approval To Pembrolizumab For Locally Recurrent Unresectable Or Metastatic Triple Negative Breast Cancer

Published: 11/13/2020 19:31 GMT
Merck & Co Inc (MRK) - FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable Or Metastatic Triple Negative Breast Cancer.
FDA - Also Approved Pd-l1 Ihc 22c3 Pharmdx As Companion Diagnostic for Selecting Patients With Tnbc for Pembrolizumab.